Literature DB >> 26485614

The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice.

Ryan P Ceddia1, DaeKee Lee1, Matthew F Maulis1, Bethany A Carboneau1, David W Threadgill1, Greg Poffenberger1, Ginger Milne1, Kelli L Boyd1, Alvin C Powers1, Owen P McGuinness1, Maureen Gannon1, Richard M Breyer1.   

Abstract

Mice carrying a targeted disruption of the prostaglandin E2 (PGE2) E-prostanoid receptor 3 (EP3) gene, Ptger3, were fed a high-fat diet (HFD), or a micronutrient matched control diet, to investigate the effects of disrupted PGE2-EP3 signaling on diabetes in a setting of diet-induced obesity. Although no differences in body weight were seen in mice fed the control diet, when fed a HFD, EP3(-/-) mice gained more weight relative to EP3(+/+) mice. Overall, EP3(-/-) mice had increased epididymal fat mass and adipocyte size; paradoxically, a relative decrease in both epididymal fat pad mass and adipocyte size was observed in the heaviest EP3(-/-) mice. The EP3(-/-) mice had increased macrophage infiltration, TNF-α, monocyte chemoattractant protein-1, IL-6 expression, and necrosis in their epididymal fat pads as compared with EP3(+/+) animals. Adipocytes isolated from EP3(+/+) or EP3(-/-) mice were assayed for the effect of PGE2-evoked inhibition of lipolysis. Adipocytes isolated from EP3(-/-) mice lacked PGE2-evoked inhibition of isoproterenol stimulated lipolysis compared with EP3(+/+). EP3(-/-) mice fed HFD had exaggerated ectopic lipid accumulation in skeletal muscle and liver, with evidence of hepatic steatosis. Both blood glucose and plasma insulin levels were similar between genotypes on a control diet, but when fed HFD, EP3(-/-) mice became hyperglycemic and hyperinsulinemic when compared with EP3(+/+) fed HFD, demonstrating a more severe insulin resistance phenotype in EP3(-/-). These results demonstrate that when fed a HFD, EP3(-/-) mice have abnormal lipid distribution, developing excessive ectopic lipid accumulation and associated insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26485614      PMCID: PMC4701878          DOI: 10.1210/en.2015-1693

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  49 in total

1.  Group X secretory phospholipase A2 regulates insulin secretion through a cyclooxygenase-2-dependent mechanism.

Authors:  Preetha Shridas; Lubna Zahoor; Kathy J Forrest; Joseph D Layne; Nancy R Webb
Journal:  J Biol Chem       Date:  2014-08-13       Impact factor: 5.157

2.  Cyclooxygenase-2, not microsomal prostaglandin E synthase-1, is the mechanism for interleukin-1β-induced prostaglandin E2 production and inhibition of insulin secretion in pancreatic islets.

Authors:  Susan Parazzoli; Jamie S Harmon; Sara N Vallerie; Tao Zhang; Huarong Zhou; R Paul Robertson
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

Review 3.  Several agents and pathways regulate lipolysis in adipocytes.

Authors:  Valéria Ernestânia Chaves; Danúbia Frasson; Nair Honda Kawashita
Journal:  Biochimie       Date:  2011-05-30       Impact factor: 4.079

Review 4.  Lipolysis in adipocytes.

Authors:  Maryam Ahmadian; Yuhui Wang; Hei Sook Sul
Journal:  Int J Biochem Cell Biol       Date:  2009-12-16       Impact factor: 5.085

Review 5.  Membrane prostaglandin E synthase-1: a novel therapeutic target.

Authors:  Bengt Samuelsson; Ralf Morgenstern; Per-Johan Jakobsson
Journal:  Pharmacol Rev       Date:  2007-09       Impact factor: 25.468

6.  Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets.

Authors:  C Dai; M Brissova; Y Hang; C Thompson; G Poffenberger; A Shostak; Z Chen; R Stein; A C Powers
Journal:  Diabetologia       Date:  2011-12-14       Impact factor: 10.122

7.  Role of insulin signaling impairment, adiponectin and dyslipidemia in peripheral and central neuropathy in mice.

Authors:  Nicholas J Anderson; Matthew R King; Lina Delbruck; Corinne G Jolivalt
Journal:  Dis Model Mech       Date:  2014-04-24       Impact factor: 5.758

8.  Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion.

Authors:  Michelle E Kimple; Mark P Keller; Mary R Rabaglia; Renee L Pasker; Joshua C Neuman; Nathan A Truchan; Harpreet K Brar; Alan D Attie
Journal:  Diabetes       Date:  2013-01-24       Impact factor: 9.461

9.  An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats.

Authors:  Abishek Iyer; Junxian Lim; Hemant Poudyal; Robert C Reid; Jacky Y Suen; Julie Webster; Johannes B Prins; Jonathan P Whitehead; David P Fairlie; Lindsay Brown
Journal:  Diabetes       Date:  2012-09       Impact factor: 9.461

Review 10.  Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.

Authors:  Un Ju Jung; Myung-Sook Choi
Journal:  Int J Mol Sci       Date:  2014-04-11       Impact factor: 5.923

View more
  30 in total

Review 1.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

2.  ErbB4 deletion predisposes to development of metabolic syndrome in mice.

Authors:  Fenghua Zeng; Yinqiu Wang; Lance A Kloepfer; Suwan Wang; Raymond C Harris
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-06-26       Impact factor: 4.310

Review 3.  Regulation of pancreatic β-cell function and mass dynamics by prostaglandin signaling.

Authors:  Bethany A Carboneau; Richard M Breyer; Maureen Gannon
Journal:  J Cell Commun Signal       Date:  2017-01-28       Impact factor: 5.782

Review 4.  The Beta Cell in Type 2 Diabetes.

Authors:  Ashley A Christensen; Maureen Gannon
Journal:  Curr Diab Rep       Date:  2019-08-09       Impact factor: 4.810

Review 5.  The EP3 Receptor/Gz Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease.

Authors:  Michael D Schaid; Jaclyn A Wisinski; Michelle E Kimple
Journal:  AAPS J       Date:  2017-06-05       Impact factor: 4.009

6.  The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity.

Authors:  Ryan P Ceddia; Jason D Downey; Ryan D Morrison; Maria P Kraemer; Sarah E Davis; Jing Wu; Craig W Lindsley; Huiyong Yin; J Scott Daniels; Richard M Breyer
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-07-02       Impact factor: 3.072

7.  PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes.

Authors:  Ramzi Hassouneh; Rania Nasrallah; Joe Zimpelmann; Alex Gutsol; David Eckert; Jamie Ghossein; Kevin D Burns; Richard L Hébert
Journal:  Diabetologia       Date:  2016-03-19       Impact factor: 10.122

8.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

9.  Regulation of arterial reactivity by concurrent signaling through the E-prostanoid receptor 3 and angiotensin receptor 1.

Authors:  Maria P Kraemer; Hyehun Choi; Jeff Reese; Fred S Lamb; Richard M Breyer
Journal:  Vascul Pharmacol       Date:  2016-05-31       Impact factor: 5.773

10.  Relationship between polymorphisms of the lipid metabolism-related gene PLA2G16 and risk of colorectal cancer in the Chinese population.

Authors:  Xiao-Nv Xie; Jing Yu; Li-Hua Zhang; Zhi-Ying Luo; Dong-Sheng Ouyang; Ling-Jie Zheng; Chun-Yang Wang; Li Yang; Ling Chen; Zhi-Rong Tan
Journal:  Funct Integr Genomics       Date:  2018-10-20       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.